{"id":"bc006","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, BC006 prevents the interaction between PD-1 and its ligands, thereby releasing the brakes on the immune system and enhancing anti-tumor activity.","oneSentence":"BC006 is a monoclonal antibody targeting the PD-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:57:51.933Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT07447102","phase":"PHASE2","title":"Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis","status":"NOT_YET_RECRUITING","sponsor":"Dragonboat Biopharmaceutical Company Limited","startDate":"2026-04-01","conditions":"Idiopathic Pulmonary Fibrosis (IPF)","enrollment":96},{"nctId":"NCT05211440","phase":"NA","title":"Microbial Enzyme Impact on Postprandial Nutrient Levels and Gastrointestinal Symptoms in Healthy Adults","status":"COMPLETED","sponsor":"University of Illinois at Urbana-Champaign","startDate":"2022-01-18","conditions":"Digestive Health, Gastrointestinal Health","enrollment":30},{"nctId":"NCT05212896","phase":"PHASE1","title":"An Exploratory Clinical Study of BC006 in Patients With Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Dragonboat Biopharmaceutical Company Limited","startDate":"2021-11-26","conditions":"Advanced Solid Tumors (Including GCTTS)","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BC006","genericName":"BC006","companyName":"Dragonboat Biopharmaceutical Company Limited","companyId":"dragonboat-biopharmaceutical-company-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BC006 is a monoclonal antibody targeting the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}